PPAP (free amine) – (784118-64-5)

Phenylpropylaminopentane is an experimental drug that belongs to the class of catecholaminergic activity enhancers (CAEs). It is a derivative of selegiline and is structurally related to amphetamine. PPAP enhances the release of norepinephrine and dopamine in the brain by stimulating impulse propagation-mediated release of these neurotransmitters. Unlike traditional stimulants, PPAP does not cause an uncontrolled flood of monoamine neurotransmitters but instead increases their release in response to neuronal stimulation.

PPAP was first described in the scientific literature in 1988 and gained prominence in the 1990s as a reference compound for studying the monoaminergic activity enhancer (MAE) system. It was found to be less potent than its successor, BPAP, which was developed in 1999 and is more selective and potent, with the added benefit of enhancing serotonin activity. Despite its potential therapeutic applications in conditions like depression, ADHD, and Alzheimer’s disease, PPAP has not been clinically studied in humans.

The drug’s mechanism of action involves agonism of the trace amine-associated receptor 1 (TAAR1), which is believed to mediate its effects on neurotransmitter release. PPAP has a higher therapeutic index in animal models compared to amphetamine, indicating a better safety profile while maintaining comparable efficacy in improving learning, retention, and antidepressant effects.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Phenylpropylaminopentane
https://pubchem.ncbi.nlm.nih.gov/compound/Phenylpropylaminopentane-hydrochloride_-_R
https://drugs.ncats.io/drug/JQS8BZ2WS9
https://www.amadischem.com/product-A977045